These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29509924)

  • 21. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Viral Suppression Among a Cohort of Adolescents and Young Adults with Behaviorally Acquired Human Immunodeficiency Virus.
    Wood SM; Lowenthal E; Lee S; Ratcliffe SJ; Dowshen N
    AIDS Patient Care STDS; 2017 Sep; 31(9):377-383. PubMed ID: 28891717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?
    Burbelo PD; Price RW; Hagberg L; Hatano H; Spudich S; Deeks SG; Gisslén M
    J Infect Dis; 2018 Mar; 217(7):1024-1032. PubMed ID: 29401308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Simon VA;
    IAPAC Mon; 2001 Aug; 7(8):235-7. PubMed ID: 11708276
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of anti-HIV antibody responses in subjects receiving antiretroviral therapy during chronic HIV-1 infection.
    Liang Y; Li L; Shui J; Hu F; Wang H; Xia Y; Cai W; Tang S
    J Clin Virol; 2020 Jul; 128():104414. PubMed ID: 32417676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To Guide.
    Wood BR
    Infect Dis Clin North Am; 2019 Sep; 33(3):693-705. PubMed ID: 31255385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.
    Ortiz GM; Hu J; Goldwitz JA; Chandwani R; Larsson M; Bhardwaj N; Bonhoeffer S; Ramratnam B; Zhang L; Markowitz MM; Nixon DF
    J Virol; 2002 Jan; 76(1):411-5. PubMed ID: 11739706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
    Adalid-Peralta L; Godot V; Colin C; Krzysiek R; Tran T; Poignard P; Venet A; Hosmalin A; Lebon P; Rouzioux C; Chene G; Emilie D;
    J Leukoc Biol; 2008 Apr; 83(4):1060-7. PubMed ID: 18182457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
    Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
    AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.
    Laanani M; Ghosn J; Essat A; Melard A; Seng R; Gousset M; Panjo H; Mortier E; Girard PM; Goujard C; Meyer L; Rouzioux C;
    Clin Infect Dis; 2015 Jun; 60(11):1715-21. PubMed ID: 25737374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
    Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
    PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
    Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
    Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.